Effects of twenty kinds of chemotherapeutic agents on the proliferation of Treg cells

doi:10.16352/j.issn.1001-6325.2023.10.1518

Abstract

Abstract: Objective To observe the effects of 20 chemotherapeutic agents on the proliferation of Treg cells. Methods Twenty agents used in routine chemotherapy were selected and assayed on IL-2- induced Treg cell proliferation through CellTrace labeling and flow cytometry. Results After treatment with 12 chemotherapeutic agents at non-cytotoxic concentration, the proportion as well as the number of Foxp3⁺Treg cells in CD4⁺ T cells were significantly reduced. Conclusions Twelve chemotherapeutic agents including 3 tubulin interfering agents, 3 transcription and RNA synthesis interfering agents and 2 topoisomerase inhibitors inhibited the proliferation of Treg cells.

Key words: cancer immunity, chemotherapy, Treg cell

CLC Number:

R979.1

HUANG Wei, LING Ruiyun, GAO Lexin, TANG Wen, QIAN Lingbo, CHEN Fengyang. Effects of twenty kinds of chemotherapeutic agents on the proliferation of Treg cells[J]. Basic & Clinical Medicine, 2023, 43(10): 1518-1521.

References 12

[1]	Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression-implications for anticancer therapy[J]. Nat Rev Clin Oncol, 2019, 16: 356-371.
[2]	Minohara K, Imai M, Matoba T, et al. Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer[J]. Cancer Sci, 2023,114:1256-1269.
[3]	Mehraj U, Dar AH, Wani NA, et al. Tumor microenvironment promotes breast cancer chemoresistance[J]. Cancer Chemother Pharmacol, 2021,87:147-158.
[4]	Galluzzi L, Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anti-cancer agents[J]. Cancer Cell,2015,28:690-714.
[5]	Li P, Chen F, Zheng J, et al. Cyclophosphamide abrogates the expansion of CD4+Foxp3+ regulatory T cells and enhances the efficacy of bleomycin in the treatment of mouse B16-F10 melanomas[J]. Cancer Biol Med, 2021,18:1010-1020.
[6]	Dees S, Ganesan R, Singh S, et al. Regulatory T cell targeting in cancer: emerging strategies in immunotherapy[J]. Eur J Immunol, 2021,51:280-291.
[7]	Eriksson E, Wenthe J, Irenaeus S, et al. Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer[J]. J Transl Med, 2016,14:282.doi:10.1186/s12967-016-1037-z.
[8]	Li JY, Duan XF, Wang LP, et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer[J]. J Immunol Res, 2014,2014:286170.doi: 10.1155/2014/286170.doi: 10.1155/2014/286170.
[9]	Zhang L, Dermawan K, Jin M, et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy[J]. Clin Immunol, 2008,129:219-229.
[10]	Kashima H, Momose F, Umehara H, et al. Epirubicin, identified using a novel luciferase reporter assay for Foxp3 inhibitors, inhibits regulatory T cell activity[J]. PLoS One, 2016,11:e0156643.doi: 10.1371/journal.pone.0156643.
[11]	Ning T, Li J, He Y, et al. Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer[J]. Mol Ther, 2021,29:2723-2736.
[12]	Ye C, Brand D, Zheng SG. Targeting IL-2: an unex-pected effect in treating immunological diseases [J]. Signal Transduct Target Ther, 2018,3:2.doi: 10.1038/s41392-017-0002-5.

[1]	LI Juan, LI Xiaofeng, XU Shengzhi, TANG Kai. Efficacy of cinobufacini capsule combined with docetaxel plus cisplatin chemotherapy for the treatment of non-small cell lung cancer [J]. Basic & Clinical Medicine, 2024, 44(2): 247-251.
[2]	. Drug therapy for intracranial germ cell tumor [J]. Basic & Clinical Medicine, 2024, 44(10): 1350-1356.
[3]	. Advances in pharmacotherapy for angiosarcoma [J]. Basic & Clinical Medicine, 2024, 44(10): 1363-1367.
[4]	. Association of seven antibody levels in lung cancer with chemotherapy effect and prognosis in patients with NSCLC [J]. Basic & Clinical Medicine, 2024, 44(10): 1383-1387.
[5]	. Clinical characteristics and prognosis of acute B-lymphoblastic leukemia complicated with chemotherapy-induced peripheral neuropathy in children [J]. Basic & Clinical Medicine, 2024, 44(10): 1394-1399.
[6]	DENG Juan, WANG Xiufang, SUN Ruiqing. Wogonin promotes Th17/Treg cell balance in rat models with autoimmune hepatitis [J]. Basic & Clinical Medicine, 2024, 44(1): 77-83.
[7]	TAN Shufen, YANG Xielan, YANG Linlin, LI Shuqing. Effects of paclitaxel combined with carboplatin on expression of VEGF and tumor markers in ovarian cancer [J]. Basic & Clinical Medicine, 2023, 43(12): 1861-1865.
[8]	ZHUANG Zhicheng, GUAN Guoxian. Ferroptosis in the treatment of colorectal cancer [J]. Basic & Clinical Medicine, 2023, 43(1): 174-177.
[9]	HE Xiao, HU Wei-jie, LYU Wen-chang, REN Yu-ping, WU Min, WU Yi-ping, ZHANG Qi. Advances on the roles of circular RNA in breast cancer [J]. Basic & Clinical Medicine, 2022, 42(3): 507-511.
[10]	REN Meng-xian, LIANG Wei, ZANG Liu-bing, WEI Xue-rui. Comparison of the effects and adverse reactions of different radiotherapy doses and concurrent chemotherapy for esophageal cancer [J]. Basic & Clinical Medicine, 2022, 42(10): 1539-1542.
[11]	LIU Yang, ZHU Yue, YAO Jing-hao, LIU Jing, ZHOU Zheng-guang, ZHAO Fu-you, YANG Yan. Effect of chemotherapy on thyroid function or structure in patients with breast cancer [J]. Basic & Clinical Medicine, 2020, 40(5): 688-691.
[12]	ZHANG Liang, LIU Ming-yong, LIU Peng, XUE Xin, ZHANG Liang-min, GUO Qiao-nan, ZHAO Jian-hua. Osteosarcoma cells can reproduce into tumorigenic cells by escaping chemotherapy-induced cell senescence [J]. Basic & Clinical Medicine, 2020, 40(2): 187-191.
[13]	. 5-Fluorouracil suppresses human hepatocellular carcinoma cell growth via promoting miR-22 expression [J]. Basic & Clinical Medicine, 2017, 37(10): 1368-1372.
[14]	. Gemcitabine suppresses glycolysis in human pancreatic cancer cells [J]. Basic & Clinical Medicine, 2016, 36(6): 752-757.
[15]	. Cisplatin suppresses human hepatocellular carcinoma cell growth via regulating microRNA-214-mediatedΒ-CATENIN axis [J]. Basic & Clinical Medicine, 2014, 34(9): 1199-1203.